關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

搜尋結果Search Result

符合「Trade show news」新聞搜尋結果, 共 3245 篇 ,以下為 2761 - 2784 篇 訂閱此列表,掌握最新動態
Utmel Attends the PCIM Europe 2023- Excelling in Power Electronics

SHENZHEN, China, April 19, 2023 /PRNewswire/ -- Utmel Electronics, a professional independent distributor of electronic components, recently announced that it will attend PCIM Europe. The exhibition will be held at the Nuremberg Exhibition Center in Germany from Tuesday, May 9th to Thursday, May 11th, 2023. Utmel will show you the strength of Utmel as a professional electronic component distributor at HALL 7 BOOTH 569, including the brand's sales channels, after-sales service, quality inspection ability, brand marketing, etc. Utmel will participate in the PCIM Europe 2023 from May 9 to 11, 2023, and the booth location is HALL 7 BOOTH 569. PCIM Europe is Europe's most influential exposition for power electronics, applications fields, smart motion, and power quality in Europe, and the world's largest power semiconductor exhibition. With the basic concept of "Power Electronics, Smart Motion, Renewable Energy, Energy Management", the exhibition aims to provide a communication platform for professionals from the power electronics industry, so that practitioners have the opportunity to contact the industry's latest research results. The range of exhibits includes semiconductors, sensing components, development software, power supplies, etc. Enterprises participating in PCIM Europe come from all over the world. It is a great honor for Utmel to be one of the participating brands. Utmel Electronics is a professional independent distributor of electronic components. Based on a powerful information network and supplier database, Utmel Electronics provides high-quality components and supply chain management services for electronic manufacturers from all over the world. By continuously optimizing enterprise management, integrating upstream supplier resources, and upgrading the enterprise service system, Utmel's achievements have been more and more recognized by society. After more than three years of development, Utmel has grown into a comprehensive power electronics brand enterprise. As an innovative enterprise growing up under the vigorous development of the new economy and new business formats, Utmel has won great praise for innovating upstream and downstream transaction services and meeting the needs of downstream end customers. Today, Utmel has a team of more than 200 employees, serving the Chinese mainland, Hong Kong, Macau, Taiwan Province, the United States, Germany, Britain, France, and other regions and countries. In the future, Utmel will also continuously and comprehensively optimize the scale of enterprise development, uphold the concept of "customer first, sincerity and integrity, innovation and enterprising, and creating a win-win situation", and strive to become the world's leading one-stop solution service provider for electronic components. Attending PCIM Europe will not only prove Utmel's highly competitive development advantages, but also further enrich Utmel's overseas service network, and help Utmel establish and develop cooperation opportunities with more peers. Now we sincerely invite all new and old customers who are interested in in-depth cooperation with electronic components distributors to come to the exhibition. As a pioneer and practitioner who has been deeply involved in the electronics industry for many years, Utmel will be waiting for you at HALL 7 BOOTH 569 to show the style of Utmel electronics and demonstrate the strength and responsibility of the enterprise.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 345 加入收藏 :
Lotus Technology showcased Eletre at Auto Shanghai 2023 after its first delivery

NEW YORK, April 19, 2023 /PRNewswire/ -- Today, Lotus Technology Inc. ("Lotus Tech" or the "Company"), a leading global luxury electric vehicle maker, showcased three vehicles at Auto Shanghai 2023. The brand displayed four models of Eletre, Lotus Tech's first fully electric hyper SUV, along with an Evija, the world's first pure electric British hyper car, and an Emira, the mid-engined sports car, Lotus's last ICE vehicle, at its 1,200 square meter booth. Lotus Tech also provided Eletre test drives to customers around the Shanghai International Exhibition Center. Lotus Tech’s booth is crowded with Auto Shanghai attendees on April 18 as the leading global luxury electric vehicle maker showcases its vehicles.   Lotus Tech booth displays for Eletre (right and middle), its first fully electric hyper SUV, and Evija (left), the world’s first pure electric British hyper car. The event came three weeks after the first delivery of Eletre, a key milestone in Lotus's transformation into an advanced, fully electric, intelligent, and sustainable luxury mobility provider. The Company is now rolling out further deliveries of Eletre across China, and will begin delivery in the UK and EU later this year. Planning is underway for future delivery to the U.S. and rest of the world, leveraging the brand's global network. As of January 31, 2023, it had received more than 5,000 Eletre orders worldwide. Lotus Tech has developed luxury EVs ahead of its traditional, internal combustion engine-focused peers by leveraging its wholly-owned R&D facilities spanning in the UK, Germany and China. Building on Lotus's racing heritage, Eletre delivers a sportscar-like experience powered by Lotus's proprietary 800-volt Electrical Performance Architecture and innovative technologies such as fully embedded L4-ready hardware with the world's first deployable LiDAR system. In addition to Eletre, the Company plans to broaden its portfolio of luxury EVs featuring groundbreaking technologies over the next four years, beginning with the expected launches of an E-segment sedan and a D-segment SUV. Lotus Tech also hosted a special ceremony at the Shanghai International Circuit F1 track on March 29 to celebrate its first delivery of Eletre, in conjunction with the 75th anniversary of the Lotus brand.  Visit the Company's website to read more and watch videos of the event. Lotus Technology Lotus Technology Inc., headquartered in Wuhan, China, has operations across China, the UK, and the EU. The Company is dedicated to delivering luxury lifestyle battery electric vehicles including SUVs and sedans with a focus on world-class R&D in next-generation automobility technologies such as electrification, digitalisation and more. Forward-Looking Statements This press release (the "Press Release") contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the U.S. Securities Exchange Act of 1934, that are based on beliefs and assumptions and on information currently available to Lotus Tech. All statements other than statements of historical fact contained in this Press Release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential", "forecast", "plan", "seek", "future", "propose" or "continue", or the negatives of these terms or variations of them or similar terminology although not all forward-looking statements contain such terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Lotus Tech and its management, as the case may be, involve inherent risks and uncertainties, including those identified in the documents filed or to be filed with the U.S. Securities and Exchange Commission by Lotus Tech. There may be additional risks that Lotus Tech does not presently know or that Lotus Tech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this Press Release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved in any specified time frame, or at all, or that any of the contemplated results of such forward-looking statements will be achieved in any specified time frame, or at all. The forward-looking statements in this Press Release represent the views of Lotus Tech as of the date they are made, and Lotus Tech undertakes no obligation to update any forward-looking statement, except as required under applicable law. Contact Information For inquiries regarding Lotus TechDemi Zhangir@group-lotus.com Brunswick GroupLotustechmedia@brunswickgroup.com

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 282 加入收藏 :
Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting

New preclinical data validate anti-tumor efficacy and intracranial activity of the drug candidate Bridge submitted an IND application to the U.S. Food and Drug Administration in March, and expects to initiate the first-in-human study of BBT-207 this year SEONGNAM, South Korea and CAMBRIDGE, Mass., April 19, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea and Cambridge that is advancing novel drugs for cancer, fibrosis, and inflammation, presented a poster with preclinical data updates of its drug candidate BBT-207 at the American Association for Cancer Research (AACR) 2023 annual meeting, being held from April 14 to 19 in Orlando, Florida. BBT-207, which has the potential to be a mutant selective and broad-spectrum fourth-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI), is the company's first internally discovered drug candidate with potent activity and efficacy against a broad range of EGFR mutations in non-small cell lung cancer (NSCLC), including C797S double mutations which arise after third-generation EGFR TKI treatment. At last year's AACR annual meeting, the company disclosed initial preclinical data for BBT-207 and discussed the potency of the drug candidate against EGFR C797S double mutations inclusive of Del19/C797S (DC) and L858R/C797S (LC) as well as driver mutations including Del19 and L858R. In this year's poster presentation, the company highlighted BBT-207's intracranial anti-tumor activity, as well as additional data showing the experimental drug's anti-tumor efficacy. In an in vivo study with an intracranial implantation model of luciferase-labeled PC-9 cells harboring EGFR Del19/T790M/C797S (DTC) mutations, BBT-207 exhibited significantly increased mouse survival rate compared to a control group. In three weeks from the baseline, both of groups treated with low-dose and high-dose of BBT-207 exhibited increased survival rate compared to the control group treated with Osimertinib. On Day 21 of the trial, the BBT-207 low-dose group, the high-dose group, and the control group exhibited 75%, 100% and 25% of the survival rate each. Also, the bioluminescence imaging data collected from the same in vivo study demonstrated that the subjects with comparative treatment showed systemic metastases including brain metastases from Week 2, whereas BBT-207 treatment groups exhibited relatively lower level of metastases. Following last year's data disclosure, both in vitro and in vivo efficacy data included in this year's poster have shown that BBT-207 boasts robust anti-tumor efficacy. BBT-207 demonstrated dose-dependent tumor regression efficacy against C797S double mutations from in vivo study with Osimertinib-resistant Ba/F3 CDX mouse models. The administration of 40mg/kg for 21 days resulted in significantly regressed tumor growth, with a tumor growth inhibition (TGI) rate of 107% in Del19/C797S (DC) model and 102% in L858R/C797S (LC) model. In DC model, tumor regression (TR) relative to the pre-treatment was observed in 8 out of 8 mice. Jimmy Jin, M.D., Ph.D., Bridge's vice president and head of discovery biology, said, "We are pleased to present BBT-207's anti-tumor efficacy results and extended survival rates in intracranial disease models. Based on our extensive experience in drug development for lung cancer, we hope that we will soon initiate the first-in-human study for BBT-207 to treat patients with metastatic non-small cell lung cancer." In March 2023, the company submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to enter a Phase 1/2 clinical trial of BBT-207. The AACR Annual Meeting, one of the world's largest academic events in oncology, is held every April for cancer researchers, scientists, and biopharma companies to share the latest cancer-related basic and clinical research. Bridge Biotherapeutics first released preclinical research data on BBT-207 at AACR last year. A copy of the poster presented at the AACR 2023 annual meeting is available at: http://bit.ly/3nVWprs The details of the presentation are as follows: Presentation Title: BBT-207, a Novel, C797X-active, 4th Generation, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) With Broad-Spectrum Activity against Treatment-Emergent as well as Drug-Naïve Mutants for the Treatment of NSCLC patients Session Category: Experimental and Molecular Therapeutics  Session Title: Tyrosine Kinase and Phosphatase Inhibitors 1  Session Date & Time: Tuesday, April 18, 2023, 9:00 a.m. -- 12:30 p.m. Abstract Number: 4018  About Bridge Biotherapeutics, Inc. Bridge Biotherapeutics Inc., based in the Republic of Korea, the U.S., and China, is a publicly-traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs including ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations. Learn more at https://www.bridgebiorx.com/en/. About BBT-207 BBT-207, a novel fourth-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) currently under IND-enabling preclinical development, is the company's first internally discovered drug candidate with potent activity and efficacy against a broad range of EGFR mutations in non-small cell lung cancer (NSCLC), including C797S mutations which arise after third-generation EGFR TKI treatment. An investigational new drug application for the first-in-human study in patients with advanced NSCLC harboring EGFR mutation after treatment with EGFR TKI, was submitted in March, 2023.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 2079 加入收藏 :
BETT 2023: ViewSonic's EdTech Ecosystem and Innovative Display Solutions Impressed the Visitors

BREA, Calif., April 19, 2023 /PRNewswire/ -- ViewSonic Corp., a leading global provider of visual solutions, has concluded a successful three-day exhibition at the BETT Show 2023 (British Educational Training and Technology Show) in London. Visitors were greatly impressed by the company's innovative EdTech solutions, especially the revolutionary 5K 105" ViewBoard interactive display, the 135" All-in-One LED Display Solution Kit with a foldable screen, as well as the latest UNIVERSE virtual campus, and myViewBoard software suite.   "ViewSonic is dedicated to partnering with the industry to offer innovative visual solutions, encompassing hardware, software, and service," said Thomas Müller, Vice President of Sales and Marketing West Europe. "At BETT, we were proud to showcase our achievements in assisting educators to overcome the challenges of digital education. Moving forward, we remain steadfast in working with our industry partners to accelerate the pace of digital transformation in the education sector." At the show, ViewSonic presented a full lineup of the ViewBoard interactive displays and the myViewBoard software suite. The most eye-catching model was the latest 21:9 5K 105" ViewBoard with a conferencing camera that provided an ideal solution for hybrid learning. The 21:9 ratio screen can be split into two screens that allow teachers to use the whiteboard and play videos at the same time. ViewSonic also showcased ViewSonic Originals, a collection of pre-made content that enables teachers to create interactive digital lessons, and in-class gamification and social-emotional learning from the collaboration with partners. Furthermore, the myViewBoard Manager and environment sensor box support schools to manage devices remotely and create an optimal learning environment. Another highlight was the 135" All-in-One LED Display Solution Kit. Its impressive foldable design allows the large screen to fit into a large passenger elevator, freight lift, as well as its movable flight case, making transportation between locations easier. The 135" display was connected to a 24" smart podium, demonstrating how teachers can write and touch intuitively on the smaller display and project their work. With its exceptional visual quality, it also made for a perfect digital backdrop. Visitors watched the keynote speeches by renowned industry experts on the massive screen, including Professor Stephen Heppell who spoke about the new way of learning, while Dr. David Whyley emphasized important strategies for school leaders. The UNIVERSE virtual campus has brought an immersive online learning experience to its visitors. In the 3D campus, teachers and students created their own avatars to interact with one another. They also experienced the platform's latest features: Thematic Classrooms, a more immersive way to learn specific school subjects, and new teacher management tools, designed to help streamline class management. During the event, ViewSonic also debuted its new UNIVERSE case study in St. Joseph's R.C. Primary School, showcasing how the platform increases student engagement and collaboration. Finally, Viewsonic shared more case studies. The Bardwell Primary School in Suffolk improved the digital learning environment with the ViewBoard and myViewBoard solutions; the Heathfield Primary School utilized myViewBoard Manager to help schools' IT staff manage all ViewBoard displays remotely. To learn more about ViewSonic's highlights at BETT 2023, please visit: https://www.youtube.com/watch?v=7CdKhQnq8gM. About ViewSonicFounded in California, ViewSonic is a leading global provider of visual solutions and conducts business in over 100 countries worldwide. As an innovator and visionary, ViewSonic is committed to providing comprehensive hardware and software solutions that include monitors, projectors, pen displays, commercial displays, All-in-One LED displays, ViewBoard interactive displays, and myViewBoard software ecosystem. With over 35 years of expertise in visual displays, ViewSonic has established a strong position for delivering innovative and reliable solutions for education, enterprise, consumer, and professional markets and helping customers "See the Difference." To find out more about ViewSonic, please visit www.viewsonic.com.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 2088 加入收藏 :
The Korea Health Industry Development Institute runs the Korean Pavilion at the 2023 HIMSS Global Health Conference and Exhibition

- Promoting the products of Korean digital healthcare companies and supporting the progress into the global market at the world's largest medical IT exhibition - CHICAGO and SEOUL, South Korea, April 19, 2023 /PRNewswire/ -- Korea Health Industry Development Institute (President Cha Soon-do, hereinafter referred to as the "Institute") announced that they will run the Korean Pavilion at the 2023 HIMSS Global Health Conference and Exhibition to be held in Chicago, USA from April 17 to 21. KHIDI at HIMSS 2023 The Korean Pavilion consists of five Korean digital healthcare companies that were selected by the evaluation committee from a pool of applicants. It will be set up at North Building Hall B (Booth 8123) in McCormick Place, and present a variety of innovative technologies, products and services in the Korean digital healthcare industry. "AIRS Medical" will showcase SwiftMR, a deep learning-based software medical device that enhances the quality of MRI videos captured through acceleration photography, "AvoMD Korea" will showcase No-Code Clinical Decision Support Platform, an AI and knowledge-based platform, "Hicarenet" will showcase Hicare Hub, a device that allows patients to connect their tablets to remote medical/home-care service, "IMedisync" will showcase iSyncWave, an AI-based wireless dry brain wave monitor, and "NGeneBio" will showcase NGeneAnalySys, a next-generation sequence listing analysis software. Haeng-Shin Lee, head of the Institute's International Medical Strategy Unit said, "We ran the Korean Pavilion at HIMSS USA last year and contributed to exporting Korean digital healthcare products," adding "We hope that outstanding domestic healthcare companies can forge global partnerships and achieve fruitful outcomes through active engagement with various buyers this year, as well." About KHIDI (Korea Health Industry Development Institute) The Institute is a public agency under the Ministry of Health and Welfare, aiming to improve the quality of the nation through the cultivation and development of national health industry, as well as the enhancement of international competitiveness. Inquiry: Kim Jiyoung, Researcher, Global Healthcare Business Team, Korea Health Industry Development Institute (jiyoungkim27@khidi.or.kr, +82-43-713-8942)

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 2069 加入收藏 :
GWM Accelerates Electrification, with World Premiere of New Energy Vehicles at Auto Shanghai 2023

BAODING, China, April 18, 2023 /PRNewswire/ -- On April 18, GWM unveiled its five major brands of HAVAL, TANK, ORA, POER, and WEY at the 20th Shanghai International Automobile Industry Exhibition ("Auto Shanghai 2023"), and released a full range of new energy models. GWM Accelerates Electrification, with World Premiere of New Energy Vehicles at Auto Shanghai 2023 GWM invited 300 medias and distributors from more than 60 countries and regions to appreciate experience of intelligent NEVs and technologies at GWM booth, during the Auto Shanghai 2023. At the ceremony, Parker Shi, the Vice President and the Head of international market of GWM, introduced to the media that GWM's transformation to new energy is in full swing, relying on the forest ecosystem. The Auto Shanghai 2023 is an excellent stage for GWM to show the achievements of intelligent to the world with more than 15 new energy vehicles unveiled. GWM HAVAL unveiled its all-new star product lineup, and the new medium new energy SUV (dubbed "Fierce Dragon MAX in Chinese market) made its world premiere. It is the first model equipped with Hi4 (Hybrid Intelligent 4WD), and adopts a fresh design concept to create a younger and more futuristic product image. GWM Pickup's new 6x6 version of GWM POER was launched together and with the large high-performance hybrid pickup POER Shanhai PHEV/HEV, which is committed to providing the best solutions for new energy pickups. GWM TANK demonstrated two NEVs, TANK400 PHEV, which celebrated its world debut, and TANK500 PHEV, a medium-to-large luxury off-road new energy SUV to be pre-sold worldwide. In addition, GWM TANK also presented the products' highlights, including off-road new energy technology and product reliability, to the audience in the form of "real scene + virtual interaction", which was recognized by the media. GWM WEY, focusing on "0 anxiety intelligent electric" category, released the first MPV model WEY Gaoshan PHEV to the world. Meanwhile, it also showcased the six-seat electric SUV Lanshan PHEV, leading the brand to forge ahead to the high-end intelligent NEV market. GWM ORA also released two pure electric models. GWM also displayed many significant technologies, such as the 3.0T V6 engine + 9HAT+P2 platform, Hi4, TANK platform, and 6×6 super off-road platform. These state-of-the-art technologies received positive reviews from media outlets and dealers. "Electrification products and advanced technologies mirror GWM's competitiveness. We look forward to bringing more GWM NEVs to local consumers in the future," said a distributor from Brazil. GWM has been upholding the idea of "be user-oriented". Based on technological innovation, it accurately understands consumer needs in the new energy era. Parker Shi noted, "Based on GWM Intelligent NEV's philosophy 'Greener, Higher, and Safer', GWM will rely on the forest ecosystem to accelerate technology iteration and product upgrading and provide global users with more high-quality and intelligent new-energy products."  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 1935 加入收藏 :
首 頁 我的收藏 搜 尋 新聞發佈